The VEGF pathway in cancer and disease: Responses, resistance, and the path forward

Cold Spring Harbor Perspectives in Medicine

Volumn 2, Issue 12, 2012, Pages

  Kieran, Mark W ^a,b   Kalluri, Raghu ^c   Cho, Yoon Jae ^d  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d LUCILE PACKARD CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; ANGIOGENESIS INHIBITOR; AXITINIB; BEVACIZUMAB; CAPECITABINE; CEDIRANIB; FLUOROURACIL; FOLINIC ACID; HUMV833; INTERFERON; JNJ 26483327; MIDOSTAURIN; MOTESANIB; OXALIPLATIN; PACLITAXEL; PAZOPANIB; PEGAPTANIB; PEGAPTANIB APTAMER; RANIBIZUMAB; SEMAXANIB; SORAFENIB; SUNITINIB; TANDUTINIB; TELATINIB; TRAP EYE; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VATALANIB; CYTOKINE;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ARTICLE; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CELL PROLIFERATION; ENDOTHELIUM CELL; GASTROINTESTINAL STROMAL TUMOR; HUMAN; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; METASTATIC COLORECTAL CANCER; NEOVASCULARIZATION (PATHOLOGY); OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RETINA MACULA AGE RELATED DEGENERATION; SIGNAL TRANSDUCTION; TUMOR GROWTH; UPREGULATION; CLINICAL TRIAL (TOPIC); DRUG ANTAGONISM; DRUG RESISTANCE; METABOLISM; NEOPLASM; PHYSIOLOGY; REVIEW; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; CLINICAL TRIALS AS TOPIC; CYTOKINES; DRUG RESISTANCE, NEOPLASM; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; TREATMENT OUTCOME; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84877296919     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a006593     Document Type: Article

References (195)

1. Ahmed SI, Thomas AL, Steward WP. 2004. Vascular endothelial growth factor (VEGF) inhibition by small molecules. J Chemother 16: 59-63.
2. Ahn GO, Brown JM. 2009. Role of endothelial progenitors and other bone marrow-derived cells in the development of the tumor vasculature. Angiogenesis 12: 159-164.
3. Aita M, Fasola G, Defferrari C, Brianti A, Bello MG, Follador A, Sinaccio G, Pronzato P, Grossi F. 2008. Targeting the VEGF pathway: Antiangiogenic strategies in the treatment of non-small cell lung cancer. Crit Rev Oncol Hematol 68: 183-196.
4. Annunziata CM, Walker AJ, Minasian L, Yu M, Kotz H, Wood BJ, Calvo K, Choyke P, Kimm D, Steinberg SM, et al. 2010. Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2. Clin Cancer Res 16: 664-672.
5. Apte RS, Modi M, Masonson H, Patel M, Whitfield L, Adamis AP. 2007. Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration. Ophthalmology 114: 1702-1712.
6. Arnold AM, Seymour L, Smylie M, Ding K, Ung Y, Findlay B, Lee CW, Djurfeldt M, Whitehead M, Ellis P, et al. 2007. Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR. 20. J Clin Oncol 25: 4278-4284.
7. Artunay O, Yuzbasioglu E, Rasier R, Sengul A, Bahcecioglu H. 2010. Posterior reversible encephalopathy syndrome after intravitreal bevacizumab injection in patient with choroidal neovascular membrane secondary to age-related maculopathy. J Ocul Pharmacol Ther 26: 301-303.
8. Azam F, Mehta S, Harris AL. 2010. Mechanisms of resistance to antiangiogenesis therapy. Eur J Cancer 46: 1323-1332.
9. Baka S, Clamp AR, Jayson GC. 2006. A review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis. Expert Opin Ther Targets 10: 867-876.
10. Barrett JM, Mangold KA, Jilling T, Kaul KL. 2005. Bi-directional interactions of prostate cancer cells and bone marrow endothelial cells in three-dimensional culture. Prostate 64: 75-82.
11. Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen PJ, Zhu M, et al. 2007. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11: 83-95.
12. Batchelor TT, Duda DG, di Tomaso E, Ancukiewicz M, Plotkin SR, Gerstner E, Eichler AF, Drappatz J, Hochberg FH, Benner T, et al. 2010. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 28: 2817-2823.
13. Berger DP, Herbstritt L, Dengler WA, Marme D, Mertelsmann R, Fiebig HH. 1995. Vascular endothelial growth factor (VEGF) mRNA expression in human tumor models of different histologies. Ann Oncol 6: 817-825.
14. Bergers G, Hanahan D. 2008. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8: 592-603.
15. Bhadada SV, Goyal BR, Patel MM. 2010. Angiogenic targets for potential disorders. Fundam Clin Pharmacol 25: 29-47.
16. Blackhall FH, O'Brien M, Schmid P, Nicolson M, Taylor P, Milenkova T, Kennedy SJ, Thatcher N. 2010. A phase I study of Vandetanib in combination with vinorelbine/cisplatin or gemcitabine/cisplatin as first-line treatment for advanced non-small cell lung cancer. J Thorac Oncol 5: 1285-1288.
17. Boehm T, Folkman J, Browder T, O'Reilly MS. 1997. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance [see comments]. Nature 390: 404-407.
18. Boehm S, Rothermundt C, Hess D, Joerger M. 2010. Antiangiogenic drugs in oncology: A focus on drug safety and the elderly-A mini-review. Gerontology 56: 303-309.
19. Boyer DS, Heier JS, Brown DM, Francom SF, Ianchulev T, Rubio RG. 2009. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology 116: 1731-1739.
20. Bozec A, Gros FX, Penault-Llorca F, Formento P, Cayre A, Dental C, Etienne-Grimaldi MC, Fischel JL, Milano G. 2008. Vertical VEGF targeting: A combination of ligand blockade with receptor tyrosine kinase inhibition. Eur J Cancer 44: 1922-1930.
21. Bradley DA, Dunn R, Nanus D, Stadler W, Dreicer R, Rosenberg J, Smith DC, Hussain M. 2007. Randomized, double-blind, placebo-controlled phase II trial of maintenance sunitinib versus placebo after chemotherapy for patients with advanced urothelial carcinoma: Scientific rationale and study design. Clin Genitourin Cancer 5: 460-463.
22. Brandes AA, Stupp R, Hau P, Lacombe D, Gorlia T, Tosoni A, Mirimanoff RO, KrosJM, van den Bent MJ. 2010. EORTC study 26041-22041: Phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma. Eur J Cancer 46: 348-354.
23. Bressler NM, Chang TS, Fine JT, Dolan CM, Ward J. 2009. Improved vision-related function after ranibizumab vs photodynamic therapy: A randomized clinical trial. Arch Ophthalmol 127: 13-21.
24. Broniscer A, Baker JN, Tagen M, Onar-Thomas A, Gilbertson RJ, Davidoff AM, Panandiker AS, Leung W, Chin TK, Stewart CF, et al. 2010. Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma. J Clin Oncol 28: 4762-4768.
25. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T. 2009. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology 116: 57-65.
26. Bukowski RM. 2009. Targeted therapies: Bevacizumab and interferon-α in metastatic renal-cell carcinoma. Nat Rev Clin Oncol 6: 253-254.
27. Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. 2007. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic Oncology Group Study. J Clin Oncol 25: 5165-5171.
28. Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, Lehman M, Adams BJ, Bello CL, DePrimo SE, et al. 2008. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 26: 1810-1816.
29. Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC, Murahashi WY, Rubio RG. 2010. Ranibizumab for macular edema following branch retinal vein occlusion: Six-month primary end point results of a phase III study. Ophthalmology 117: 1102-1112.
30. Cao Y. 2009. Tumor angiogenesis and molecular targets for therapy. Front Biosci 14: 3962-3973.
31. Chan A. 2009. Antiangiogenic therapy for metastatic breast cancer: Current status and future directions. Drugs 69: 167-181.
32. Choueiri TK. 2008. Axitinib, a novel anti-angiogenic drug with promising activity in various solid tumors. Curr Opin Investig Drugs 9: 658-671.
33. Ciulla TA, Rosenfeld PJ. 2009. Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. Curr Opin Ophthalmol 20: 158-165.
34. Cohen EE, Davis DW, Karrison TG, Seiwert TY, Wong SJ, Nattam S, Kozloff MF, Clark JI, Yan DH, Liu W, et al. 2009a. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: A phase I/II study. Lancet Oncol 10: 247-257.
35. Cohen MH, Shen YL, Keegan P, Pazdur R. 2009b. FDA drug approval summary: Bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist 14: 1131-1138.
36. Cooney MM, Tserng KY, Makar V, McPeak RJ, Ingalls ST, Dowlati A, Overmoyer B, McCrae K, Ksenich P, Lavertu P, et al. 2005. A phase IB clinical and pharmacokinetic study of the angiogenesis inhibitor SU5416 and paclitaxel in recurrent or metastatic carcinoma of the head and neck. Cancer Chemother Pharmacol 55: 295-300.
37. Czito BG, Bendell JC, Willett CG, Morse MA, Blobe GC, Tyler DS, Thomas J, LudwigKA, Mantyh CR, Ashton J, et al. 2007. Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results. Int J Radiat Oncol Biol Phys 68: 472-478.
38. Dadgostar H, Waheed N. 2008. The evolving role of vascular endothelial growth factor inhibitors in the treatment of neovascular age-related macular degeneration. Eye (Lond) 22: 761-767.
39. de Boer R, Humblet Y, Wolf J, Nogova L, Ruffert K, Milenkova T, Smith R, Godwood A, Vansteenkiste J. 2009. An open-label study of vandetanib with pemetrexed in patients with previously treated non-small-cell lung cancer. Ann Oncol 20: 486-491.
40. De Val S, Black BL. 2009. Transcriptional control of endothelial cell development. Dev Cell 16: 180-195.
41. Diaz-Flores L, Gutierrez R, Madrid JF, Varela H, Valladares F, Acosta E, Martin-Vasallo P, Diaz-Flores L Jr. 2009. Pericytes. Morphofunction, interactions and pathology in a quiescent and activated mesenchymal cell niche. Histol Histopathol 24: 909-969.
42. Dickler MN, Rugo HS, Eberle CA, Brogi E, Caravelli JF, Panageas KS, Boyd J, Yeh B, Lake DE, Dang CT, et al. 2008. A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer. Clin Cancer Res 14: 7878-7883.
43. Drappatz J, Norden AD, Wong ET, Doherty LM, Lafrankie DC, Ciampa A, Kesari S, Sceppa C, Gerard M, Phan P, et al. 2010. Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma. Int J Radiat Oncol Biol Phys 78: 85-90.
44. Drevs J, Siegert P, Medinger M, Mross K, Strecker R, Zirrgiebel U, Harder J, Blum H, Robertson J, Jurgensmeier JM, et al. 2007. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol 25: 3045-3054.
45. Dvorak HF. 2005. Angiogenesis: Update 2005. J Thromb Haemost 3: 1835-1842.
46. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, et al. 2007. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356: 125-134.
47. Eskens FA, Steeghs N, Verweij J, Bloem JL, Christensen O, van Doorn L, Ouwerkerk J, de Jonge MJ, Nortier JW, Kraetzschmar J, et al. 2009. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor β, and c-Kit, in patients with advanced or metastatic solid tumors. J Clin Oncol 27: 4169-4176.
48. Fabbro D, Ruetz S, Bodis S, Pruschy M, Csermak K, Man A, Campochiaro P, WoodJ, O'Reilly T, Meyer T. 2000. PKC412-a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des 15: 17-28.
49. Faivre S, Demetri G, Sargent W, Raymond E. 2007. Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 6: 734-745.
50. Ferrara N, Henzel WJ. 1989. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 161: 851-858.
51. Ferrara N, Gerber HP, LeCouter J. 2003. The biology of VEGF and its receptors. Nat Med 9: 669-676.
52. Fiedler W, Mesters R, Tinnefeld H, Loges S, Staib P, Duhrsen U, Flasshove M, Ottmann OG, Jung W, Cavalli F, et al. 2003. A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood 102: 2763-2767.
53. Fiedler W, Serve H, Dohner H, Schwittay M, Ottmann OG, O'Farrell AM, Bello CL, Allred R, Manning WC, Cherrington JM, et al. 2005. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 105: 986-993.
54. Fiedler W, Mesters R, Heuser M, Ehninger G, Berdel WE, Zirrgiebel U, Robertson JD, Puchalski TA, Collins B, Jurgensmeier JM, et al. 2010. An open-label, Phase I study of cediranib (RECENTIN) in patients with acute myeloid leukemia. Leuk Res 34: 196-202.
55. Folkman J. 1971. Tumor angiogenesis: Therapeutic implications. N Engl J Med 285: 1182-1186.
56. Folkman J. 1995. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27-31.
57. Fountzilas G, Fragkoulidi A, Kalogera-Fountzila A, Nikolaidou M, Bobos M, Calderaro J, Andreiuolo F, Marselos M. 2010. A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer. Cancer Chemother Pharmacol 65: 649-660.
58. Fujimoto A, Onodera H, Mori A, Nagayama S, Yonenaga Y, Tachibana T. 2006. Tumour plasticity and extravascular circulation in ECV304 human bladder carcinoma cells. Anticancer Res 26: 59-69.
59. Fury MG, Zahalsky A, Wong R, Venkatraman E, Lis E, Hann L, Aliff T, Gerald W, Fleisher M, Pfister DG. 2007. A Phase II study of SU5416 in patients with advanced or recurrent head and neck cancers. Invest New Drugs 25: 165-172.
60. Garcia-Saenz JA, Martin M, Calles A, Bueno C, Rodriguez L, Bobokova J, CustodioA, Casado A, Diaz-Rubio E. 2008. Bevacizumab in combination with metronomic chemotherapy in patients with anthracycline-and taxane-refractory breast cancer. J Chemother 20: 632-639.
61. Geiger-Gritsch S, Stollenwerk B, Miksad R, Guba B, Wild C, Siebert U. 2010. Safety of bevacizumab in patients with advanced cancer: A meta-analysis of randomized controlled trials. Oncologist 15: 1179-1191.
62. Gerber PA, Hippe A, Buhren BA, Muller A, Homey B. 2009. Chemokines in tumor-associated angiogenesis. Biol Chem 390: 1213-1223.
63. Giles FJ, Cooper MA, Silverman L, Karp JE, Lancet JE, Zangari M, Shami PJ, KhanKD, Hannah AL, Cherrington JM, et al. 2003a. Phase II study of SU5416-a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor-in patients with refractory myeloproliferative diseases. Cancer 97: 1920-1928.
64. Giles FJ, Stopeck AT, Silverman LR, Lancet JE, Cooper MA, Hannah AL, Cherrington JM, O'Farrell AM, Yuen HA, Louie SG, et al. 2003b. SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood 102: 795-801.
65. Giles FJ, List AF, Carroll M, Cortes JE, Valickas J, Chen BL, Masson E, Jacques C, Laurent D, Albitar M, et al. 2007. PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia. Leuk Res 31: 891-897.
66. Glade Bender JL, Adamson PC, Reid JM, Xu L, Baruchel S, Shaked Y, Kerbel RS, Cooney-Qualter EM, Stempak D, Chen HX, et al. 2008. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: A Children's Oncology Group Study. J Clin Oncol 26: 399-405.
67. Grothey A, Galanis E. 2009. Targeting angiogenesis: Progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol 6: 507-518.
68. Gryziewicz L. 2005. Regulatory aspects of drug approval for macular degeneration. Adv Drug Deliv Rev 57: 2092-2098.
69. Gururangan S, Chi SN, Young Poussaint T, Onar-Thomas A, Gilbertson RJ, Vajapeyam S, Friedman HS, Packer RJ, Rood BN, Boyett JM, et al. 2010. Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: A Pediatric Brain Tumor Consortium study. J Clin Oncol 28: 3069-3075.
70. Hall AP, Westwood FR, Wadsworth PF. 2006. Review of the effects of anti-angiogenic compounds on the epiphyseal growth plate. Toxicol Pathol 34: 131-147.
71. Hapani S, Chu D, Wu S. 2009. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: A meta-analysis. Lancet Oncol 10: 559-568.
72. Hapani S, Sher A, Chu D, Wu S. 2010. Increased risk of serious hemorrhage with bevacizumab in cancer patients: A meta-analysis. Oncology 79: 27-38.
73. Hendrix MJ, Seftor EA, Hess AR, Seftor RE. 2003. Vasculogenic mimicry and tumour-cell plasticity: Lessons from melanoma. Nat Rev Cancer 3: 411-421.
74. Herbst RS, Sun Y, Eberhardt WE, Germonpre P, Saijo N, Zhou C, Wang J, Li L, Kabbinavar F, Ichinose Y, et al. 2010. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): A double-blind, randomised, phase 3 trial. Lancet Oncol 11: 619-626.
75. Heymach JV, Desai J, Manola J, Davis DW, McConkey DJ, Harmon D, Ryan DP, Goss G, Quigley T, Van den Abbeele AD, et al. 2004. Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas. Clin Cancer Res 10: 5732-5740.
76. Heymach JV, Johnson BE, Prager D, Csada E, Roubec J, Pesek M, Spasova I, BelaniCP, Bodrogi I, Gadgeel S, et al. 2007. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol 25: 4270-4277.
77. Heymach JV, Paz-Ares L, De Braud F, Sebastian M, Stewart DJ, Eberhardt WE, Ranade AA, Cohen G, Trigo JM, Sandler AB, et al. 2008. Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 26: 5407-5415.
78. Hida K, Hida Y, Amin DN, Flint AF, Panigrahy D, Morton CC, Klagsbrun M. 2004. Tumor-associated endothelial cells with cytogenetic abnormalities. Cancer Res 64: 8249-8255.
79. Ho QT, Kuo CJ. 2007. Vascular endothelial growth factor: Biology and therapeutic applications. Int J Biochem Cell Biol 39: 1349-1357.
80. Hoff PM, Wolff RA, Bogaard K, Waldrum S, Abbruzzese JL. 2006. A Phase I study of escalating doses of the tyrosine kinase inhibitor semaxanib (SU5416) in combination with irinotecan in patients with advanced colorectal carcinoma. Jpn J Clin Oncol 36: 100-103.
81. Holden SN, Eckhardt SG, Basser R, de Boer R, Rischin D, Green M, Rosenthal MA, Wheeler C, Barge A, Hurwitz HI. 2005. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann Oncol 16: 1391-1397.
82. Horti J, Widmark A, Stenzl A, Federico MH, Abratt RP, Sanders N, Pover GM, Bodrogi I. 2009. A randomized, double-blind, placebo-controlled phase II study of vandetanib plus docetaxel/prednisolone in patients with hormone-refractory prostate cancer. Cancer Biother Radiopharm 24: 175-180.
83. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, et al. 2004. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342.
84. Hutson TE, Davis ID, Machiels JP, De Souza PL, Rottey S, Hong BF, Epstein RJ, Baker KL, McCann L, Crofts T, et al. 2010. Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol 28: 475-480.
85. Iwamoto FM, Lamborn KR, Robins HI, Mehta MP, Chang SM, Butowski NA, Deangelis LM, Abrey LE, Zhang WT, Prados MD, et al. 2010. Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). Neuro Oncol 12: 855-861.
86. Izzedine H, Rixe O, Billemont B, Baumelou A, Deray G. 2007. Angiogenesis inhibitor therapies: Focus on kidney toxicity and hypertension. Am J Kidney Dis 50: 203-218.
87. Izzedine H, Ederhy S, Goldwasser F, Soria JC, Milano G, Cohen A, Khayat D, Spano JP. 2009. Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol 20: 807-815.
88. Jain RK, Duda DG, Clark JW, Loeffler JS. 2006. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 3: 24-40.
89. Jayson GC, Mulatero C, Ranson M, Zweit J, Jackson A, Broughton L, Wagstaff J, Hakansson L, Groenewegen G, Lawrance J, et al. 2005. Phase I investigation of recombinant anti-human vascular endothelial growth factor antibody in patients with advanced cancer. Eur J Cancer 41: 555-563.
90. Josson S, Matsuoka Y, Chung LW, Zhau HE, Wang R. 2010. Tumor-stroma co-evolution in prostate cancer progression and metastasis. Semin Cell Dev Biol 21: 26-32.
91. Kaiser PK, Blodi BA, Shapiro H, Acharya NR. 2007a. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 114: 1868-1875.
92. Kaiser PK, Brown DM, Zhang K, Hudson HL, Holz FG, Shapiro H, Schneider S, Acharya NR. 2007b. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol 144: 850-857.
93. Karcher S, Steiner HH, Ahmadi R, Zoubaa S, Vasvari G, Bauer H, Unterberg A, Herold-Mende C. 2006. Different angiogenic phenotypes in primary and secondary glioblastomas. Int J Cancer 118: 2182-2189.
94. Kassmeyer S, Plendl J, Custodis P, Bahramsoltani M. 2009. New insights in vascular development: Vasculogenesis and endothelial progenitor cells. Anat Histol Embryol 38: 1-11.
95. Kessler T, Bayer M, Schwoppe C, Liersch R, Mesters RM, Berdel WE. 2010. Compounds in clinical Phase III and beyond. Recent Results Cancer Res 180: 137-163.
96. Kieran MW, Supko JG, Wallace D, Fruscio R, Poussaint TY, Phillips P, Pollack I, Packer R, Boyett JM, Blaney S, et al. 2009. Phase I study of SU5416, a small molecule inhibitor of the vascular endothelial growth factor receptor (VEGFR) in refractory pediatric central nervous system tumors. Pediatr Blood Cancer 52: 169-176.
97. Kindler HL, Friberg G, Singh DA, Locker G, Nattam S, Kozloff M, Taber DA, Karrison T, Dachman A, Stadler WM, et al. 2005. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 23: 8033-8040.
98. Kitamura R, Asanoma H, Nagayama S, Otagiri M. 2008. Identification of human liver cytochrome P450 isoforms involved in autoinduced metabolism of the antiangiogenic agent (Z)-5-[(1, 2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2, 4-dimethyl-1H-pyrro le-3-propanoic acid (TSU-68). Drug Metab Dispos 36: 1003-1009.
99. Kiura K, Nakagawa K, Shinkai T, Eguchi K, Ohe Y, Yamamoto N, Tsuboi M, YokotaS, Seto T, Jiang H, et al. 2008. A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer. J Thorac Oncol 3: 386-393.
100. Klagsbrun M, Takashima S, Mamluk R. 2002. The role of neuropilin in vascular and tumor biology. Adv Exp Med Biol 515: 33-48.
101. Konings IR, de Jonge MJ, Burger H, van der Gaast A, van Beijsterveldt LE, WinklerH, Verweij J, Yuan Z, Hellemans P, Eskens FA. 2010. Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours. Br J Cancer 103: 987-992.
102. Kontovinis LF, Papazisis KT, Touplikioti P, Andreadis C, Mouratidou D, KortsarisAH. 2009. Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: Clinical outcomes and plasma angiogenesis markers. BMC Cancer 9: 82. doi: 10. 1186/1471-2407-9-82.
103. Kornblau SM, Womble M, Qiu YH, Jackson CE, Chen W, Konopleva M, Estey EH, Andreeff M. 2006. Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. Blood 108: 2358-2365.
104. Kourlas H, Abrams P. 2007. Ranibizumab for the treatment of neovascular age-related macular degeneration: a review. Clin Ther 29: 1850-1861.
105. Kovacs MJ, Reece DE, Marcellus D, Meyer RM, Mathews S, Dong RP, Eisenhauer E. 2006. A phase II study of ZD6474 (Zactima), a selective inhibitor of VEGFR and EGFR tyrosine kinase in patients with relapsed multiple myeloma-NCIC CTG IND. 145. Invest New Drugs 24: 529-535.
106. Kowanetz M, Ferrara N. 2006. Vascular endothelial growth factor signaling pathways: Therapeutic perspective. Clin Cancer Res 12: 5018-5022.
107. Kuenen BC, Tabernero J, Baselga J, Cavalli F, Pfanner E, Conte PF, Seeber S, Madhusudan S, Deplanque G, Huisman H, et al. 2003. Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma. Clin Cancer Res 9: 1648-1655.
108. Kulke MH, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J, Bergsland E, Stuart K, Tye L, Huang X, et al. 2008. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 26: 3403-3410.
109. Kuo CJ, Farnebo F, Yu EY, Christofferson R, Swearingen RA, Carter R, von Recum HA, Yuan J, Kamihara J, Flynn E, et al. 2001. Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer. Proc Natl Acad Sci 98: 4605-4610.
110. Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, Davis JL, FlynnHW Jr., Esquiabro M. 2009. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: Year 2 of the PrONTO Study. Am J Ophthalmol 148: 43-58.
111. Langenberg MH, Witteveen PO, Lankheet NA, Roodhart JM, Rosing H, van den Heuvel IJ, Beijnen JH, Voest EE. 2010. Phase 1 study of combination treatment with PTK 787/ZK 222584 and cetuximab for patients with advanced solid tumors: Safety, pharmacokinetics, pharmacodynamics analysis. Neoplasia 12: 206-213.
112. Lara PN, Quinn DI, Margolin K, Meyers FJ, Longmate J, Frankel P, Mack PC, TurrellC, Valk P, Rao J, et al. 2003. SU5416 plus interferon α in advanced renal cell carcinoma: A phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition. Clin Cancer Res 9: 4772-4781.
113. Lawler J, Detmar M. 2004. Tumor progression: The effects of thrombospondin-1 and-2. Int J Biochem Cell Biol 36: 1038-1045.
114. Lee D. 2005. Phase II data with ZD6474, a small-molecule kinase inhibitor of epidermal growth factor receptor and vascular endothelial growth factor receptor, in previously treated advanced non-small-cell lung cancer. Clin Lung Cancer 7: 89-91.
115. Leek RD, Harris AL, Lewis CE. 1994. Cytokine networks in solid human tumors: Regulation of angiogenesis. J Leukoc Biol 56: 423-435.
116. Lindsay CR, MacPherson IR, Cassidy J. 2009. Current status of cediranib: The rapid development of a novel anti-angiogenic therapy. Future Oncol 5: 421-432.
117. Lockhart AC, Rothenberg ML, Dupont J, Cooper W, Chevalier P, Sternas L, BuzenetG, Koehler E, Sosman JA, Schwartz LH, et al. 2010. Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. J Clin Oncol 28: 207-214.
118. Lohela M, Bry M, Tammela T, Alitalo K. 2009. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol 21: 154-165.
119. Los M, Roodhart JM, Voest EE. 2007. Target practice: Lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. Oncologist 12: 443-450.
120. Lubner SJ, Mahoney MR, Kolesar JL, Loconte NK, Kim GP, Pitot HC, Philip PA, PicusJ, Yong WP, Horvath L, et al. 2010. Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: A phase II Consortium study. J Clin Oncol 28: 3491-3497.
121. Mackay HJ, Tinker A, Winquist E, Thomas G, Swenerton K, Oza A, Sederias J, Ivy P, Eisenhauer EA. 2010. A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND. 184. Gynecol Oncol 116: 163-167.
122. Maeshima Y, Colorado PC, Torre A, Holthaus KA, Grunkemeyer JA, Ericksen MB, Hopfer H, Xiao Y, Stillman IE, Kalluri R. 2000. Distinct antitumor properties of a type IV collagen domain derived from basement membrane. J Biol Chem 275: 21340-21348.
123. Maione F, Molla F, Meda C, Latini R, Zentilin L, Giacca M, Seano G, Serini G, Bussolino F, Giraudo E. 2009. Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse models. J Clin Invest 119: 3356-3372.
124. Matsumoto T, Claesson-Welsh L. 2001. VEGF receptor signal transduction. Sci STKE 2001: re21.
125. Miao HQ, Soker S, Feiner L, Alonso JL, Raper JA, Klagsbrun M. 1999. Neuropilin-1 mediates collapsin-1/semaphorin III inhibition of endothelial cell motility: Functional competition of collapsin-1 and vascular endothelial growth factor-165. J Cell Biol 146: 233-242.
126. Michael M, Gibbs P, Smith R, Godwood A, Oliver S, Tebbutt N. 2009. Open-label phase I trial of vandetanib in combination with mFOLFOX6 in patients with advanced colorectal cancer. Invest New Drugs 27: 253-261.
127. Miletic H, Niclou SP, Johansson M, Bjerkvig R. 2009. Anti-VEGF therapies for malignant glioma: Treatment effects and escape mechanisms. Expert Opin Ther Targets 13: 455-468.
128. Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, Dickler M, Overmoyer BA, Reimann JD, Sing AP, et al. 2005a. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23: 792-799.
129. Miller KD, Trigo JM, Wheeler C, Barge A, Rowbottom J, Sledge G, Baselga J. 2005b. A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer. Clin Cancer Res 11: 3369-3376.
130. Mita MM, Rowinsky EK, Forero L, Eckhart SG, Izbicka E, Weiss GR, Beeram M, MitaAC, de Bono JS, Tolcher AW, et al. 2007. A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma. Cancer Chemother Pharmacol 59: 165-174.
131. Motzer RJ, Molina AM. 2009. Targeting renal cell carcinoma. J Clin Oncol 27: 3274-3276.
132. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, GinsbergMS, Kim ST, Baum CM, DePrimo SE, et al. 2006. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24: 16-24.
133. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, et al. 2007. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356: 115-124.
134. Mross K, Drevs J, Muller M, Medinger M, Marme D, Hennig J, Morgan B, LebwohlD, Masson E, Ho YY, et al. 2005. Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours. Eur J Cancer 41: 1291-1299.
135. Murakami M, Simons M. 2008. Fibroblast growth factor regulation of neovascularization. Curr Opin Hematol 15: 215-220.
136. Natale RB, Bodkin D, Govindan R, Sleckman BG, Rizvi NA, Capo A, Germonpre P, Eberhardt WE, Stockman PK, Kennedy SJ, et al. 2009. Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: Results from a two-part, double-blind, randomized phase ii study. J Clin Oncol 27: 2523-2529.
137. Nguyen QD, Shah SM, Browning DJ, Hudson H, Sonkin P, Hariprasad SM, Kaiser P, Slakter JS, Haller J, Do DV, et al. 2009. A phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration. Ophthalmology 116: 2141-2148.
138. Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, CiampaAS, Ebbeling LG, Levy B, Drappatz J, et al. 2008. Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence. Neurology 70: 779-787.
139. O'Donnell A, Padhani A, Hayes C, Kakkar AJ, Leach M, Trigo JM, Scurr M, RaynaudF, Phillips S, Aherne W, et al. 2005. A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points. Br J Cancer 93: 876-883.
140. O'Farrell AM, Yuen HA, Smolich B, Hannah AL, Louie SG, Hong W, Stopeck AT, Silverman LR, Lancet JE, Karp JE, et al. 2004. Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia. Leuk Res 28: 679-689.
141. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J. 1994. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma [see comments]. Cell 79: 315-328.
142. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, BirkheadJR, Olsen BR, Folkman J. 1997. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277-285.
143. Pande A, Lombardo J, Spangenthal E, Javle M. 2007. Hypertension secondary to anti-angiogenic therapy: Experience with bevacizumab. Anticancer Res 27: 3465-3470.
144. Patel PJ, Bunce C, Tufail A. 2008. A randomised, double-masked phase III/IV study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularisation secondary to age-related macular degeneration: Clinical trial design. Trials 9: 56. doi: 10. 1186/1745-6215-9-56.
145. Peterson AC, Swiger S, Stadler WM, Medved M, Karczmar G, Gajewski TF. 2004. Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma. Clin Cancer Res 10: 4048-4054.
146. Philip PA. 2008. Targeted therapies for pancreatic cancer. Gastrointest Cancer Res 2: S16-S19.
147. Ping G, Hui-Min W, Wei-Min W, Bao-Hui H. 2010. Sunitinib in pretreated advanced non-small-cell lung carcinoma: A primary result from Asian population. Med Oncol 28: 578-583.
148. Polyzos A. 2008. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors. J Steroid Biochem Mol Biol 108: 261-266.
149. Porta C, Paglino C, Imarisio I, Ferraris E. 2009. Sorafenib tosylate in advanced kidney cancer: Past, present and future. Anticancer Drugs 20: 409-415.
150. Ramjaun AR, Hodivala-Dilke K. 2009. The role of cell adhesion pathways in angiogenesis. Int J Biochem Cell Biol 41: 521-530.
151. Ribatti D. 2009. Endogenous inhibitors of angiogenesis: A historical review. Leuk Res 33: 638-644.
152. Ribatti D, Nico B, Crivellato E. 2009. Morphological and molecular aspects of physiological vascular morphogenesis. Angiogenesis 12: 101-111.
153. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS, Archer L, AtkinsJN, Picus J, Czaykowski P, et al. 2008. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 26: 5422-5428.
154. Rini BI, Wilding G, Hudes G, Stadler WM, Kim S, Tarazi J, Rosbrook B, Trask PC, Wood L, Dutcher JP. 2009. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol 27: 4462-4468.
155. Robinson BG, Paz-Ares L, Krebs A, Vasselli J, Haddad R. 2010a. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab 95: 2664-2671.
156. Robinson ES, Matulonis UA, Ivy P, Berlin ST, Tyburski K, Penson RT, Humphreys BD. 2010b. Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor. Clin J Am Soc Nephrol 5: 477-483.
157. Roboz GJ, Giles FJ, List AF, Cortes JE, Carlin R, Kowalski M, Bilic S, Masson E, Rosamilia M, Schuster MW, et al. 2006. Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Leukemia 20: 952-957.
158. Rosen LS, Kurzrock R, Mulay M, Van Vugt A, Purdom M, Ng C, Silverman J, Koutsoukos A, Sun YN, Bass MB, et al. 2007. Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol 25: 2369-2376.
159. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY. 2006. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355: 1419-1431.
160. Roskoski R Jr. 2008. VEGF receptor protein-tyrosine kinases: Structure and regulation. Biochem Biophys Res Commun 375: 287-291.
161. Rossi L, Zoratto F, Papa A, Iodice F, Minozzi M, Frati L, Tomao S. 2010. Current approach in the treatment of hepatocellular carcinoma. World J Gastrointest Oncol 2: 348-359.
162. Sadda SR, Stoller G, Boyer DS, Blodi BA, Shapiro H, Ianchulev T. 2010. Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age-related macular degeneration in the 2-year anchor study. Retina 30: 1390-1399.
163. Samaras V, Piperi C, Levidou G, Zisakis A, Kavantzas N, Themistocleous MS, Boviatsis EI, Barbatis C, Lea RW, Kalofoutis A, Korkolopoulou P, et al. 2009. Analysis of interleukin (IL)-8 expression in human astrocytomas: Associations with IL-6, cyclooxygenase-2, vascular endothelial growth factor, and microvessel morphometry. Hum Immunol 70: 391-397.
164. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. 2006. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355: 2542-2550.
165. Saunders MP, Wilson R, Peeters M, Smith R, Godwood A, Oliver S, Van Cutsem E. 2009. Vandetanib with FOLFIRI in patients with advanced colorectal adenocarcinoma: Results from an open-label, multicentre Phase I study. Cancer Chemother Pharmacol 64: 665-672.
166. Scott IU, Edwards AR, Beck RW, Bressler NM, Chan CK, Elman MJ, Friedman SM, Greven CM, Maturi RK, Pieramici DJ, et al. 2007. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 114: 1860-1867.
167. Semenza GL. 2007. Vasculogenesis, angiogenesis, and arteriogenesis: Mechanisms of blood vessel formation and remodeling. J Cell Biochem 102: 840-847.
168. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. 1983. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219: 983-985.
169. Sharma S, Freeman B, Turner J, Symanowski J, Manno P, Berg W, Vogelzang N. 2009. A phase I trial of PTK787/ZK222584 in combination with pemetrexed and cisplatin in patients with advanced solid tumors. Invest New Drugs 27: 63-65.
170. Shepard DR, Cooney MM, Elson P, Bukowski RM, Dreicer R, Rini BI, Garcia JA. 2010. A phase II study of tandutinib (MLN518), a selective inhibitor of type III tyrosine receptor kinases, in patients with metastatic renal cell carcinoma. Invest New Drugs doi: 10. 1007/s10637-010-9516-1.
171. Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG, Licitra L, Eschenberg MJ, Sun YN, Juan T, et al. 2008. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 359: 31-42.
172. Sloan B, Scheinfeld NS. 2008. Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy. Curr Opin Investig Drugs 9: 1324-1335.
173. Socinski MA, Novello S, Brahmer JR, Rosell R, Sanchez JM, Belani CP, Govindan R, Atkins JN, Gillenwater HH, Pallares C, et al. 2008. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 26: 650-656.
174. Sozzani S, Rusnati M, Riboldi E, Mitola S, Presta M. 2007. Dendritic cell-endothelial cell cross-talk in angiogenesis. Trends Immunol 28: 385-392.
175. Stadler WM, Cao D, Vogelzang NJ, Ryan CW, Hoving K, Wright R, Karrison T, Vokes EE. 2004. A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer. Clin Cancer Res 10: 3365-3370.
176. Summers J, Cohen MH, Keegan P, Pazdur R. 2010. FDA drug approval summary: Bevacizumab plus interferon for advanced renal cell carcinoma. Oncologist 15: 104-111.
177. Tabernero J. 2007. The role of VEGF and EGFR inhibition: Implications for combining anti-VEGF and anti-EGFR agents. Mol Cancer Res 5: 203-220.
178. Tamura T, Minami H, Yamada Y, Yamamoto N, Shimoyama T, Murakami H, Horiike A, Fujisaka Y, Shinkai T, Tahara M, et al. 2006. A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors. J Thorac Oncol 1: 1002-1009.
179. Thomas AL, Morgan B, Horsfield MA, Higginson A, Kay A, Lee L, Masson E, Puccio-Pick M, Laurent D, Steward WP. 2005. Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. J Clin Oncol 23: 4162-4171.
180. Thompson EM, Dosa E, Kraemer DF, Neuwelt EA. 2010. Correlation of MRI sequences to assess progressive glioblastoma multiforme treated with bevacizumab. J Neurooncol 103: 353-360.
181. Timar J, Dome B. 2008. Antiangiogenic drugs and tyrosine kinases. Anticancer Agents Med Chem 8: 462-469.
182. Ton NC, Jayson GC. 2004. Resistance to anti-VEGF agents. Curr Pharm Des 10: 51-64.
183. van Cruijsen H, Voest EE, Punt CJ, Hoekman K, Witteveen PO, Meijerink MR, Puchalski TA, Robertson J, Saunders O, Jurgensmeier JM, et al. 2010. Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours. Eur J Cancer 46: 901-911.
184. Van Meter ME, Kim ES. 2010. Bevacizumab: Current updates in treatment. Curr Opin Oncol 22: 586-591.
185. Varker KA, Biber JE, Kefauver C, Jensen R, Lehman A, Young D, Wu H, Lesinski GB, Kendra K, Chen HX III, et al. 2007. A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma. Ann Surg Oncol 14: 2367-2376.
186. Verhoeff JJ, van Tellingen O, Claes A, Stalpers LJ, van Linde ME, Richel DJ, Leenders WP, van Furth WR. 2009. Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme. BMC Cancer 9: 444. doi: 10. 1186/1471-2407-9-444.
187. Veronese ML, Mosenkis A, Flaherty KT, Gallagher M, Stevenson JP, TownsendRR, O'Dwyer PJ. 2006. Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol 24: 1363-1369.
188. Voss MJ, Niggemann B, Zanker KS, Entschladen F. 2010. Tumour reactions to hypoxia. Curr Mol Med 10: 381-386.
189. Vredenburgh JJ, Desjardins A, Herndon JE II., Dowell JM, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Wagner M, et al. 2007. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13: 1253-1259.
190. Wary KK. 2004. Molecular targets for anti-angiogenic therapy. Curr Opin Mol Ther 6: 54-70.
191. Wells SA Jr., Gosnell JE, Gagel RF, Moley J, Pfister D, Sosa JA, Skinner M, Krebs A, Vasselli J, Schlumberger M. 2010. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 28: 767-772.
192. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, et al. 2010. Updated response assessment criteria for high-grade gliomas: Response assessment in neuro-oncology working group. J Clin Oncol 28: 1963-1972.
193. Yan L, Anderson GM, DeWitte M, Nakada MT. 2006. Therapeutic potential of cytokine and chemokine antagonists in cancer therapy. Eur J Cancer 42: 793-802.
194. Yla-Herttuala S, Rissanen TT, Vajanto I, Hartikainen J. 2007. Vascular endothelial growth factors: Biology and current status of clinical applications in cardiovascular medicine. J Am Coll Cardiol 49: 1015-1026.
195. Zangari M, Anaissie E, Stopeck A, Morimoto A, Tan N, Lancet J, Cooper M, Hannah A, Garcia-Manero G, Faderl S, et al. 2004. Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma. Clin Cancer Res 10: 88-95.